Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Leading pharmaceutical giants Pfizer and AstraZeneca have unveiled significant investment plans for France, totaling almost $1 billion. These announcements were made in anticipation of the annual 'Choose France' business summit, signaling a robust vote of confidence in the French economy by two of the world's foremost healthcare companies.
Pfizer's Pledge to French R&D
MSN reported that Pfizer has committed to investing 500 million euros ($538.5 million) in France, focusing on enhancing its research and development (R&D) capabilities within the country. This move aims to solidify France's position as a key player in the global healthcare research landscape, significantly boosting the local economy and job market.
AstraZeneca's Dunkirk Investment
Similarly, AstraZeneca announced an investment of $388 million to develop its Dunkirk site. This financial infusion is expected to expand the company's manufacturing and production capacities in France, further establishing the country as a critical hub in AstraZeneca's international operations.
The 'Choose France' Initiative
CNBC noted that these announcements arrived just as President Emmanuel Macron was gearing up to inaugurate the 'Choose France' event on Monday. Aiming to attract major overseas businesses and investors, the initiative underscores France's ambition to strengthen its appeal as a global business and investment destination.
Earlier statements also highlighted Morgan Stanley's creation of 100 new jobs in Paris and commitments from other international firms, such as German aviation innovator Lilium.
France's Global Business Ambition
Under President Macron's leadership, France is keen to enhance its stature as a premier European business capital, competing against traditional heavyweights like New York and London. Despite Paris's 14th place ranking in the recent Z/Yen global financial centers survey, these substantial investments by Pfizer and AstraZeneca are poised to contribute significantly to France's ambition of climbing the ranks as a top destination for global finance and business.
Photo: Pfizer Newsroom
